Literature DB >> 3978322

An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation.

J W Black, P Leff, N P Shankley, J Wood.   

Abstract

An operational model of pharmacological agonism has been analysed to predict the behaviour of rectangular hyperbolic and non-hyperbolic agonist-concentration effect, E/[A], curves with variation in receptor concentration, [Ro]. Irreversible antagonism is predicted to cause E/[A] curve gradient changes in non-hyperbolic cases but not in hyperbolic cases; in both cases estimation of agonist dissociation constants (KAS) is theoretically valid. 5-Hydroxytryptamine (5-HT) produced "steep' E/[A] curves in contracting the rabbit isolated aorta preparation. Irreversible antagonism by phenoxybenzamine (Pbz) produced a flattened E/[A] curve, consistent with theoretical predictions. Fitting 5-HT E/[A] curves in the presence and absence of Pbz to the model provided an estimate of KA for 5-HT which was not significantly different from the estimate obtained using Furchgott's null method. The operational model of agonism appears to account qualitatively and quantitatively for the effects of [Ro] changes on hyperbolic and non-hyperbolic E/[A] curves. Under conditions where irreversible antagonism may be used to estimate KAS, fitting the operational model directly to E/[A] data represents a valid, economical and analytically simple alternative to the conventional null method.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978322      PMCID: PMC1987296          DOI: 10.1111/j.1476-5381.1985.tb12941.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  THE CHANGES IN RESPONSE AND IN IONIC CONTENT OF SMOOTH MUSCLE PRODUCED BY ACETYLCHOLINE ACTON AND BY CALCIUM DEFICIENCY.

Authors:  W D PATON; A M ROTHSCHILD
Journal:  Br J Pharmacol Chemother       Date:  1965-04

2.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

3.  A modification of receptor theory.

Authors:  R P STEPHENSON
Journal:  Br J Pharmacol Chemother       Date:  1956-12

4.  Analysis of dose-response curves and calculation of agonist dissociation constants using a weighted nonlinear curve fitting program.

Authors:  G A McPherson; P Molenaar; C Raper; E Malta
Journal:  J Pharmacol Methods       Date:  1983-12

5.  Operational models of pharmacological agonism.

Authors:  J W Black; P Leff
Journal:  Proc R Soc Lond B Biol Sci       Date:  1983-12-22

6.  Is Ro 03-7894 an irreversible antagonist at beta-adrenoceptor sites?

Authors:  E Krstew; G A McPherson; E Malta; P Molenaar; C Raper
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

7.  The affinity and efficacy of onium salts on the frog rectus abdominis.

Authors:  R B Barlow; N C Scott; R P Stephenson
Journal:  Br J Pharmacol Chemother       Date:  1967-09

8.  Noradrenergic component in the vasoconstriction induced by 5-hydroxytryptamine in goat cerebral arteries.

Authors:  J Marin; M Salaices; B Gómez; S Lluch
Journal:  J Pharm Pharmacol       Date:  1981-11       Impact factor: 3.765

9.  An action of 5-hydroxytryptamine on adrenaline receptors.

Authors:  I R INNES
Journal:  Br J Pharmacol Chemother       Date:  1962-12

10.  Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta.

Authors:  E Apperley; P P Humphrey; G P Levy
Journal:  Br J Pharmacol       Date:  1976-10       Impact factor: 8.739

View more
  88 in total

1.  Mechanism-based modeling of adaptive changes in the pharmacodynamics of midazolam in the kindling model of epilepsy.

Authors:  A Cleton; P H Van der Graaf; W Ghijsen; R Voskuyl; M Danhof
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

2.  Mechanism-based modeling of functional adaptation upon chronic treatment with midazolam.

Authors:  A Cleton; J Odman; P H Van der Graaf; W Ghijsen; R Voskuyl; M Danhof
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

3.  An analysis of glucocorticoid receptor-mediated gene expression in BEAS-2B human airway epithelial cells identifies distinct, ligand-directed, transcription profiles with implications for asthma therapeutics.

Authors:  T Joshi; M Johnson; R Newton; M Giembycz
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

4.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

5.  Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action.

Authors:  Y J Liu; N P Shankley; N J Welsh; J W Black
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

Review 6.  Modeling cell signaling networks.

Authors:  Narat J Eungdamrong; Ravi Iyengar
Journal:  Biol Cell       Date:  2004-06       Impact factor: 4.458

7.  Agonist/antagonist interactions with cloned human 5-HT1A receptors: variations in intrinsic activity studied in transfected HeLa cells.

Authors:  H W Boddeke; A Fargin; J R Raymond; P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

Review 8.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 9.  The mass action equation in pharmacology.

Authors:  Terry Kenakin
Journal:  Br J Clin Pharmacol       Date:  2015-12-21       Impact factor: 4.335

10.  Discrimination by benextramine between the NPY-Y1 receptor subtypes present in rabbit isolated vas deferens and saphenous vein.

Authors:  S Palea; M Corsi; J M Rimland; D G Trist
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.